Evidence map›Paper›PMID 30130377›Full record

ArticlePLoS medicine2018

Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysis.

Avery I McIntosh, Helen E Jenkins, Laura F White, Marinus Barnard, Dana R Thomson, Tania Dolby, John Simpson, Elizabeth M Streicher, Mary B Kleinman, Elizabeth J Ragan and 4 more

Abstract read
In one paragraph

Article in PLoS medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Avery I McIntoshDepartment of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America.
Helen E JenkinsDepartment of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America.
Laura F WhiteDepartment of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America.ORCID 0000-0002-0588-8235
Marinus BarnardNational Health Laboratory Service, Cape Town, South Africa.
Dana R ThomsonDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, United States of America.ORCID 0000-0002-9507-9123
Tania DolbyNational Health Laboratory Service, Cape Town, South Africa.
John SimpsonNational Health Laboratory Service, Cape Town, South Africa.
Elizabeth M StreicherDST/NRF Centre of Excellence for Biomedical Tuberculosis Research/SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0003-3901-1981
Mary B KleinmanSection of Infectious Diseases, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, United States of America.
Elizabeth J RaganSection of Infectious Diseases, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, United States of America.
Paul D van HeldenDST/NRF Centre of Excellence for Biomedical Tuberculosis Research/SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Megan B MurrayDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, United States of America.ORCID 0000-0003-0443-1986
Robin M WarrenDST/NRF Centre of Excellence for Biomedical Tuberculosis Research/SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Karen R JacobsonSection of Infectious Diseases, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, United States of America.ORCID 0000-0003-4239-3685

Funding

Interdisciplinary Training for BiostatisticiansT32GM074905 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI WHITE, LAURA FORSBERG · 2005 to 2019
$3.0M
Supplement to Methods to Estimate the Effect of Interventions on the Incidence and Transmission of TuberculosisR01GM122876 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI WHITE, LAURA FORSBERG · 2017 to 2021
$1.9M
Geospatial clustering and molecular and social epidemiology of drug resistant TBK01TW009213 · FIC · MASSACHUSETTS GENERAL HOSPITAL · PI JACOBSON, KAREN R · 2011 to 2015
$715k
Understanding spatial heterogeneity of drug resistant tuberculosisK01AI102944 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI JENKINS, HELEN E. · 2013 to 2017
$627k
FIC NIH HHS K01 TW009213NIAID NIH HHS K01 AI102944NIGMS NIH HHS R01 GM122876NIGMS NIH HHS T32 GM074905
6 · The paper itself

Abstract

backgroundSouth Africa has the highest tuberculosis incidence globally (781/100,000), with an estimated 4.3% of cases being rifampicin resistant (RR). Control and elimination strategies will require detailed spatial information to understand where drug-resistant tuberculosis exists and why it persists in those communities. We demonstrate a method to enable drug-resistant tuberculosis monitoring by identifying high-burden communities in the Western Cape Province using routinely collected laboratory data. METHODS AND

findingsWe retrospectively identified cases of microbiologically confirmed tuberculosis and RR-tuberculosis from all biological samples submitted for tuberculosis testing (n = 2,219,891) to the Western Cape National Health Laboratory Services (NHLS) between January 1, 2008, and June 30, 2013. Because the NHLS database lacks unique patient identifiers, we performed a series of record-linking processes to match specimen records to individual patients. We counted an individual as having a single disease episode if their positive samples came from within two years of each other. Cases were aggregated by clinic location (n = 302) to estimate the percentage of tuberculosis cases with rifampicin resistance per clinic. We used inverse distance weighting (IDW) to produce heatmaps of the RR-tuberculosis percentage across the province. Regression was used to estimate annual changes in the RR-tuberculosis percentage by clinic, and estimated average size and direction of change was mapped. We identified 799,779 individuals who had specimens submitted from mappable clinics for testing, of whom 222,735 (27.8%) had microbiologically confirmed tuberculosis. The study population was 43% female, the median age was 36 years (IQR 27-44), and 10,255 (4.6%, 95% CI: 4.6-4.7) cases had documented rifampicin resistance. Among individuals with microbiologically confirmed tuberculosis, 8,947 (4.0%) had more than one disease episode during the study period. The percentage of tuberculosis cases with rifampicin resistance documented among these individuals was 11.4% (95% CI: 10.7-12.0). Overall, the percentage of tuberculosis cases that were RR-tuberculosis was spatially heterogeneous, ranging from 0% to 25% across the province. Our maps reveal significant yearly fluctuations in RR-tuberculosis percentages at several locations. Additionally, the directions of change over time in RR-tuberculosis percentage were not uniform. The main limitation of this study is the lack of unique patient identifiers in the NHLS database, rendering findings to be estimates reliant on the accuracy of the person-matching algorithm.

conclusionsOur maps reveal striking spatial and temporal heterogeneity in RR-tuberculosis percentages across this province. We demonstrate the potential to monitor RR-tuberculosis spatially and temporally with routinely collected laboratory data, enabling improved resource targeting and more rapid locally appropriate interventions.

Indexed as

AdultAntitubercular AgentsData CollectionEpidemiological MonitoringFemaleGeographic Information SystemsHumansIncidenceIsoniazidMaleRetrospective StudiesRifampinSouth AfricaSpatio-Temporal AnalysisTuberculosis, Multidrug-ResistantAntitubercular AgentsIsoniazidRifampin

Identifiers

PMID30130377
PMCPMC6103505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.